secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0001193125-24-011699
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Apellis appoints Adam Townsend as Chief Operating Officer, effective immediately
--------------------------------------------------------------------------------

- Adam Townsend, 47, previously Chief Commercial Officer since Nov 2018, assumes additional COO role.
- Townsend's background includes senior leadership roles at Biogen, including SVP of Corporate Development.
- No family relationships with directors or executive officers, and no reportable transactions.
- Appointment effective January 16, 2024, by the Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312524011699/0001193125-24-011699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312524011699/d696780d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-011699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer